Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia

被引:78
作者
Krueger, Stefan
Papassotiriou, Jana
Marre, Reinhard
Richter, Klaus
Schumann, Christian
von Baum, Heike
Morgenthaler, Nils G.
Suttorp, Norbert
Welte, Tobias
机构
[1] Univ Klinikum Aachen, Med Klin 1, D-52057 Aachen, Germany
[2] Univ Hosp Ulm, Dept Internal Med, Ulm, Germany
[3] Brahms AG, Res Dept, Hennigsdorf, Germany
[4] Univ Hosp Ulm, Dept Med Microbial & Hyg, Ulm, Germany
[5] Univ Med Berlin, Charite, Dept Internal Med Infect Dis & Pulm Med, Berlin, Germany
[6] Hannover Med Sch, Dept Pneumol, Univ Clin Hannover, D-3000 Hannover, Germany
关键词
community-acquired pneumonia; atrial natriuretic peptide; vasopressin; copeptin; C-reactive protein; procalcitonin; CRB-65; score;
D O I
10.1007/s00134-007-0895-5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Community acquired pneumonia (CAP) is the most important clinical infection. Therefore, the CAP competence network CAPNETZ was instituted in Germany. The aim of this substudy was to evaluate the value of pro-atrial natriuretic peptide (MR-proANP) and pro-vasopressin (CT-proAVP) for severity assessment and outcome prediction in CAP. Design: Prospective observational study. Setting: German CAP competence network CAPNETZ. Methods: We enrolled 589 patients (age 61 +/- 18 years, 46% female) with proven CAP. MR-proANP, CT-proAVP, C-reactive protein (CRP), procalcitonin (PCT) and CRB-65 score were determined on admission. Results: MR-proANP, CT-proAVP and PCT levels, but not CRP, increased with increasing severity of CAP, classified according to the CRB-65 score. In patients who died during 28-day follow-up, median MR-proANP and CT-proAVP levels (respectively 237.0 vs. 93.5 pmol/l and 44.2 vs. 12.4 pmol/l, each p < 0.0001) were significantly higher than in survivors. In receiver operating characteristic (ROC) analysis for survival, the area under the curve (AUC) values for CT-proAVP (0.86, 95% CI 0.83-0.89) and MR-proANP (0.76, 95% CI 0.72-0.80) were similar to the AUC of CRB-65 (0.73, 95% CI 0.70-0.77). In multivariable Cox proportional-hazards regression analyses including MR-proANP/CTproAVP, coexisting illnesses and CRB-65, increased MR-proANP and CT-proAVP concentrations were the strongest predictors of mortality. Conclusions: MR-proANP and CT-proAVP are useful new biomarkers for the risk stratification of CAP patients. They are significantly lower in CAP survivors and correlate with the severity of the disease measured by CRB-65 score.
引用
收藏
页码:2069 / 2078
页数:10
相关论文
共 37 条
[1]   Epidemiology of community-acquired pneumonia in adults:: a population-based study [J].
Almirall, J ;
Bolíbar, I ;
Vidal, J ;
Sauca, G ;
Coll, P ;
Niklasson, B ;
Bartolomé, M ;
Balanzo, X .
EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (04) :757-763
[2]   A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women [J].
Baik, I ;
Curhan, GC ;
Rimm, EB ;
Bendich, A ;
Willett, WC ;
Fawzi, WW .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (20) :3082-3088
[3]   CRB-65 predicts death from community-acquired pneumonia [J].
Bauer, T. T. ;
Ewig, S. ;
Marre, R. ;
Suttorp, N. ;
Welte, T. .
JOURNAL OF INTERNAL MEDICINE, 2006, 260 (01) :93-101
[4]   Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia [J].
Boussekey, N ;
Leroy, O ;
Alfandari, S ;
Devos, P ;
Georges, H ;
Guery, B .
INTENSIVE CARE MEDICINE, 2006, 32 (03) :469-472
[5]   Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis [J].
Brueckmann, M ;
Huhle, G ;
Lang, S ;
Haase, KK ;
Bertsch, T ;
Weiss, C ;
Kaden, JJ ;
Putensen, C ;
Borggrefe, M ;
Hoffmann, U .
CIRCULATION, 2005, 112 (04) :527-534
[6]   A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia [J].
Buising, KL ;
Thursky, KA ;
Black, JF ;
MacGregor, L ;
Street, AC ;
Kennedy, MP ;
Brown, GV .
THORAX, 2006, 61 (05) :419-424
[7]   Validation of a predictive rule for the management of community-acquired pneumonia [J].
Capelastegul, A ;
España, PP ;
Quintana, JM ;
Areltio, I ;
Gorordo, I ;
Egurrola, M ;
Bilbao, A .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) :151-157
[8]   A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study [J].
Cheng, V ;
Kazanagra, R ;
Garcia, A ;
Lenert, L ;
Krishnaswamy, P ;
Gardetto, N ;
Clopton, P ;
Maisel, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :386-391
[9]   Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting [J].
Dao, Q ;
Krishnaswamy, P ;
Kazanegra, R ;
Harrison, A ;
Amirnovin, R ;
Lenert, L ;
Clopton, P ;
Alberto, J ;
Hlavin, P ;
Maisel, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :379-385
[10]   Assessment of pneumonia severity: a European perspective [J].
Ewig, S ;
Torres, A ;
Woodhead, M .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) :6-8